Acromegaly: the disease, its impact on patients, and managing the burden of long-term treatment

References

• MelmedSMedical progress: acromegalyN Engl J Med2006355242558257317167139
   PubMed Web of Science ®Google Scholar
• ChansonPSalenaveSKamenickyPCazabatLYoungJPituitary tumours: acromegalyBest Pract Res Clin Endocrinol Metab200923555557419945023
   PubMed Web of Science ®Google Scholar
• International Diabetes Federation (IDF)IDF Diabetes Atlas5th edBrusselsIDF2011
   Google Scholar
• NachtigallLDelgadoASwearingenBLeeHZeriklyRKlibanskiAChanging patterns in diagnosis and therapy of acromegaly over two decadesJ Clin Endocrinol Metab20089362035204118381584
   PubMed Web of Science ®Google Scholar
• KatznelsonLAtkinsonJLCookDMEzzatSZHamrahianAHMillerKKAmerican Association of Clinical EndocrinologistsAmerican Association of Clinical Endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of acromegaly – 2011 updateEndocr Pract201117 Suppl 414421846616
   PubMed Web of Science ®Google Scholar
• GiustinaAChansonPBronsteinMDAcromegaly Consensus GroupA consensus on criteria for cure of acromegalyJ Clin Endocrinol Metab20109573141314820410227
   PubMed Web of Science ®Google Scholar
• MelmedSColaoABarkanAAcromegaly Consensus GroupGuidelines for acromegaly management: an updateJ Clin Endocrinol Metab20099451509151719208732
   PubMed Web of Science ®Google Scholar
• Davi’MVDalle CarbonareLGiustinaASleep apnoea syndrome is highly prevalent in acromegaly and only partially reversible after biochemical control of the diseaseEur J Endocrinol2008159553354018765561
   PubMed Web of Science ®Google Scholar
• RokkasTPistiolasDSechopoulosPMargantinisGKoukoulisGRisk of colorectal neoplasm in patients with acromegaly: a meta-analysisWorld J Gastroenterol200814223484348918567075
   PubMed Web of Science ®Google Scholar
• SherlockMAyukJTomlinsonJWMortality in patients with pituitary diseaseEndocr Rev201031330134220086217
   PubMed Web of Science ®Google Scholar
• DrangeMRFramNRHerman-BonertVMelmedSPituitary tumor registry: a novel clinical resourceJ Clin Endocrinol Metab200085116817410634382
   PubMed Web of Science ®Google Scholar
• FredaPUReyesCMNuruzzamanATSundeenREBruceJNBasal and glucose-suppressed GH levels less than 1 microg/L in newly diagnosed acromegalyPituitary20036417518015237928
   PubMedGoogle Scholar
• NomikosPBuchfelderMFahlbuschRThe outcome of surgery in 668 patients with acromegaly using current criteria of biochemical “cure.”Eur J Endocrinol2005152337938715757854
   PubMed Web of Science ®Google Scholar
• Ipsen Somatuline^® Depot [prescribing information]Silver Spring, MDUS Food and Drug Administration (FDA)2011 Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022074s003lbl.pdfAccessed September 28, 2012
   Google Scholar
• Novartis Sandostatin^® LAR Depot [prescribing information]Silver Spring, MDFDA2011 Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021008s025lbl.pdfAccessed September 28, 2012
   Google Scholar
• MaizaJCVezzosiDMattaMLong-term (up to 18 years) effects on GH/IGF-1 hypersecretion and tumour size of primary somatostatin analogue (SSTa) therapy in patients with GH-secreting pituitary adenoma responsive to SSTaClin Endocrinol (Oxf)200767228228917524029
   PubMed Web of Science ®Google Scholar
• CaronPCogneMRaingeardIBex-BachellerieVKuhnJMEffectiveness and tolerability of 3-year lanreotide Autogel treatment in patients with acromegalyClin Endocrinol2006642209214
   PubMed Web of Science ®Google Scholar
• MercadoMBorgesFBouterfaHSMS995B2401 Study GroupA prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR (long-acting repeatable octreotide) in the primary therapy of patients with acromegalyClin Endocrinol2007666859868
   PubMed Web of Science ®Google Scholar
• MurrayRDMelmedSA critical analysis of clinically available somatostatin analog formulations for therapy of acromegalyJ Clin Endocrinol Metab20089382957296818477663
   PubMed Web of Science ®Google Scholar
• Pzifer Somavert^® [prescribing information]Silver Spring, MDFDA2012 Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021106s031lbl.pdfAccessed September 28, 2012
   Google Scholar
• Novartis Parlodel^® [prescribing information]Silver Spring, MDFDA2012 Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/017962s065s068lbl.pdfAccessed September 28, 2012
   Google Scholar
• Pfizer Dostinex^® [prescribing information]Silver Spring, MDFDA2011 Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020664s012lbl.pdfAccessed September 28, 2012
   Google Scholar
• LoefflerJSShihHARadiation therapy in the management of pituitary adenomasJ Clin Endocrinol Metab20119671992200321525155
   PubMed Web of Science ®Google Scholar
• PetitJHBillerBMCoenJJProton stereotactic radiosurgery in management of persistent acromegalyEndocr Pract200713772673418194929
   PubMedGoogle Scholar
• JagannathanJSheehanJPPouratianNLawsERJrSteinerLVanceMLGamma knife radiosurgery for acromegaly: outcomes after failed transsphenoidal surgeryNeurosurgery200862612621269 discussion 1262–126918824992
   PubMed Web of Science ®Google Scholar
• PollockBEJacobJTBrownPDNippoldtTBRadiosurgery of growth hormone-producing pituitary adenomas: factors associated with biochemical remissionJ Neurosurg2007106583383817542527
   PubMed Web of Science ®Google Scholar
• Ben-ShlomoASheppardMCStephensJMPulgarSMelmedSClinical, quality of life, and economic value of acromegaly disease controlPituitary201114328429421597975
   PubMed Web of Science ®Google Scholar
• MazziottiGFlorianiIBonadonnaSTorriVChansonPGiustinaAEffects of somatostatin analogs on glucose homeostasis: a metaanalysis of acromegaly studiesJ Clin Endocrinol Metab20099451500150819208728
   PubMed Web of Science ®Google Scholar
• RowlesSVPrietoLBadiaXShaletSMWebbSMTrainerPJQuality of life (QOL) in patients with acromegaly is severely impaired: use of a novel measure of QOL: acromegaly quality of life questionnaireJ Clin Endocrinol Metab20059063337334115755865
   PubMed Web of Science ®Google Scholar
• WebbSMBadiaXSurinachNLSpanish AcroQoL Study GroupValidity and clinical applicability of the acromegaly quality of life questionnaire, AcroQoL: a 6-month prospective studyEur J Endocrinol2006155226927716868140
   PubMed Web of Science ®Google Scholar
• Kauppinen-MäkelinRSaneTSintonenHQuality of life in treated patients with acromegalyJ Clin Endocrinol Metab200691103891389616849407
   PubMed Web of Science ®Google Scholar
• SieversCIsingMPfisterHPersonality in patients with pituitary adenomas is characterized by increased anxiety-related traits: comparison of 70 acromegalic patients with patients with non-functioning pituitary adenomas and age- and gender-matched controlsEur J Endocrinol2009160336737319073833
   PubMed Web of Science ®Google Scholar
• BiermaszNRPereiraAMSmitJWRomijnJARoelfsemaFMorbidity after long-term remission for acromegaly: persisting joint-related complaints cause reduced quality of lifeJ Clin Endocrinol Metab20059052731273915741257
   PubMed Web of Science ®Google Scholar
• WassenaarMJBiermaszNRKloppenburgMClinical osteoarthritis predicts physical and psychological QoL in acromegaly patientsGrowth Horm IGF Res201020322623320194043
   PubMed Web of Science ®Google Scholar
• LombardiGMinutoFTamburranoGEfficacy of the new long-acting formulation of lanreotide (lanreotide Autogel) in somatostatin analogue-naive patients with acromegalyJ Endrocrinol Invest2009323202209
   Web of Science ®Google Scholar
• GhigoEBillerBMColaoAComparison of pegvisomant and long-acting octreotide in patients with acromegaly naïve to radiation and medical therapyJ Endocrinol Invest2009321192493320009494
   PubMed Web of Science ®Google Scholar
• NeggersSJvan AkenMOde HerderWWQuality of life in acromegalic patients during long-term somatostatin analog treatment with and without pegvisomantJ Clin Endocrinol Metab200893103853385918647806
   PubMed Web of Science ®Google Scholar
• WexlerTGunnellLOmerZGrowth hormone deficiency is associated with decreased quality of life in patients with prior acromegalyJ Clin Endocrinol Metab20099472471247719366847
   PubMed Web of Science ®Google Scholar
• MillerKMWexlerTFazeliPGrowth hormone deficiency after treatment of acromegaly: a randomized, placebo-controlled study of growth hormone replacementJ Clin Endocrinol Metab201095256757720061426
   PubMed Web of Science ®Google Scholar
• HuaSCYanYHChangTCAssociations of remission status and lanreotide treatment with quality of life in patients with treated acromegalyEur J Endocrinol2006155683183717132752
   PubMed Web of Science ®Google Scholar
• NovartisSandostatin^® LAR Depot: nurse home injection program (NHIP) for eligible patients with acromegaly [web page on the Internet]East Hanover, NJNovartis nd Available from: http://www.us.sandostatin.com/patient/disease/acromegaly/nhip.jspAccessed November 15, 2012
   Google Scholar
• SalvatoriRNachtigallLBCookDMSALSA Study GroupEffectiveness of self- or partner-administration of an extended-release aqueous-gel formulation of lanreotide in lanreotide-naïve patients with acromegalyPituitary201013211512219898989
   PubMed Web of Science ®Google Scholar
• HighamCEThomasJDBidlingmaierMDrakeWMTrainerPJSuccessful use of weekly pegvisomant administration in patients with acromegalyEur J Endocrinol20091611212519411301
   PubMed Web of Science ®Google Scholar
• HarrisAGDalyAFTreatment of acromegalyAcromegaly and its managementPhiladelphia, PALippincott-Raven19964968
   Google Scholar
• MolitchMEClinical manifestations of acromegalyEndocrinol Metab Clin North Am19922135976141521514
   PubMed Web of Science ®Google Scholar